Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: all 142 studies

Page 1 of 2. Open to participants first (72), then studies with results posted, then the rest; newest registration first within each.

• Qualitative Study With Focus Groups of People Living With ANCA-associated Vasculitis (AAV) and Clinicians, to Explore Different Perspectives on Shared Decision-making in AAV.Not yet recruitingNCT07859995
• FT839 in Autoimmune DiseasesRecruitingNCT07800871Phase 1/2
• Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated GlomerulonephritisRecruitingNCT07746180Phase 2
• Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular ResearchNot yet recruitingNCT07737470
• CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune DiseasesNot yet recruitingNCT07596680Early Phase 1
• MTS109 in Patients With Refractory Autoimmune DiseasesRecruitingNCT07526350Early Phase 1
• Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseRecruitingNCT07507201Early Phase 1
• Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune DiseasesNot yet recruitingNCT07490275Phase 1
• Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.Not yet recruitingNCT07451847Phase 4
• YTS109 in Pediatric Relapsed/Refractory Autoimmune DiseasesNot yet recruitingNCT07439029Phase 1
• A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney DiseasesNot yet recruitingNCT07389499Early Phase 1
• Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney InvolvementNot yet recruitingNCT07373262Phase 3
• CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesRecruitingNCT07315087Phase 1
• CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune DiseaseRecruitingNCT07305116Phase 1
• Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune DiseasesRecruitingNCT07301164Early Phase 1
• PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated VasculitisRecruitingNCT07258524
• Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune DeficienciesRecruitingNCT07251179
• Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune DiseasesRecruitingNCT07246096Early Phase 1
• Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune DiseasesRecruitingNCT07236801Phase 1
• An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune DiseasesRecruitingNCT07236762Phase 1
• A Study of CD19 UCAR-T Cells in Subjects With Autoimmune DiseasesNot yet recruitingNCT07212322Not applicable
• A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.RecruitingNCT07203404Early Phase 1
• BDB-001 Phase III Trial in ANCA-Associated VasculitisRecruitingNCT07168161Phase 3
• Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisRecruitingNCT07160608Phase 2
• (68)Ga-FAPI PET/CT in Patients With ANCA-associated VasculitisRecruitingNCT07151521
• Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and EfficacyRecruitingNCT07150000
• A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune DiseasesRecruitingNCT07123519Phase 1
• A Clinical Study of YTS109 Cell for R/R Autoimmune DiseasesRecruitingNCT07104721Phase 1
• Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersRecruitingNCT07089121Phase 1/2
• EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular DiseasesRecruitingNCT07077304
• SGLT-2 Inhibitors on Albuminuria in Chronic Kidney Disease Patients With Lupus Nephritis and ANCA- Associated VasculitisNot yet recruitingNCT07035834Phase 4
• The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated VasculitisNot yet recruitingNCT07033299Phase 1
• Epithelial Dysmetabolism and Renal Fibrosis in ANCA VasculitisRecruitingNCT07010250
• Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAVNot yet recruitingNCT06986018Early Phase 1
• Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)RecruitingNCT06983821Phase 3
• A Study of OL-108 in Relapsed/Refractory Autoimmune DiseasesRecruitingNCT06980597Phase 1
• UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune DiseasesNot yet recruitingNCT06978738Phase 1
• A Clinical Study of YTS109 Cell in R/R Autoimmune DiseasesRecruitingNCT06978647Phase 1
• CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune DiseasesRecruitingNCT06941129Phase 1
• Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune DiseasesRecruitingNCT06828042Phase 1/2
• Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune DiseasesNot yet recruitingNCT06821659Phase 1/2
• Early-access Avacopan in Real-world ANCA-associated VasculitisRecruitingNCT06794827
• BCMA-CD19 CAR-T Therapy for Refractory Autoimmune DiseasesRecruitingNCT06794008Phase 2
• Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune DiseasesRecruitingNCT06775912Early Phase 1
• A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)RecruitingNCT06733935Phase 1/2
• AYLo - AutoimmunitY and Loss of yRecruitingNCT06696027
• Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune DiseasesRecruitingNCT06685042Phase 1/2
• Rare AutoImmune SElf-management Programme DevelopmentRecruitingNCT06642870
• Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune DiseasesRecruitingNCT06614270Not applicable
• Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated VasculitisRecruitingNCT06611696Phase 4
• Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune DiseasesRecruitingNCT06548607Early Phase 1
• Neutrophil Extracellular Traps in Different Forms of Systemic SclerosisRecruitingNCT06462768
• The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune DiseasesNot yet recruitingNCT06420154Early Phase 1
• An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune DiseaseRecruitingNCT06379646Not applicable
• A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune DiseaseEnrolling by invitationNCT06375993Phase 1
• Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune DiseaseRecruitingNCT06373081Not applicable
• Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)RecruitingNCT06350110Phase 1/2
• Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune DiseasesRecruitingNCT06316076Phase 1
• A Phase 1 Study of FT819 in B-cell Mediated Autoimmune DiseaseRecruitingNCT06308978Phase 1
• The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney DiseasesRecruitingNCT06285279Phase 1
• Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T CellsRecruitingNCT06277427Not applicable
• Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)Not yet recruitingNCT06226662Phase 2
• A Study to Evaluate Avacopan in Participants With ANCA-associated VasculitisRecruitingNCT06072482Phase 4
• Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune DiseaseRecruitingNCT06056921Phase 1
• Stratified Therapy on Pediatric AAGNRecruitingNCT05969522Phase 4
• Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)RecruitingNCT05965284Phase 4
• Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)RecruitingNCT05962840Phase 4
• A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO TrialRecruitingNCT05946564Phase 3
• Biocollection of Patients With ANCA Associated VasculitisRecruitingNCT05364892Not applicable
• Multicenter Cohort Study of AAV in Hunan of ChinaRecruitingNCT05315141
• Study of Salvage Therapy to Treat Patients With Granulomatosis With PolyangiitisRecruitingNCT04871191Phase 3
• Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic VasculitisRecruitingNCT02257866
• PR3-AAV Resilient Remission or PRRRTerminatedNCT05376319Phase 2Results posted
• Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.CompletedNCT04413149Results posted
• Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA VasculitisTerminatedNCT03906227Not applicableResults posted
• A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated VasculitisCompletedNCT02994927Phase 3Results posted
• Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab DosingTerminatedNCT02749292Phase 4Results posted
• Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated VasculitisCompletedNCT02222155Phase 2Results posted
• Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated VasculitisCompletedNCT02169219Phase 4Results posted
• The Assessment of Prednisone In Remission Trial - Centers of Excellence ApproachCompletedNCT01940094Phase 3Results posted
• Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)TerminatedNCT01934504Results posted
• Rituximab Vasculitis Maintenance StudyCompletedNCT01697267Phase 3Results posted
• CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated VasculitisActive, not recruitingNCT07388277Phase 1/2
• the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune DiseasesActive, not recruitingNCT07339540Early Phase 1
• Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPAActive, not recruitingNCT06868290Phase 2
• A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune DiseasesWithdrawnNCT06866080Early Phase 1
• Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune DiseasesSuspendedNCT06549296Early Phase 1
• A Study of RD06-04 in Patients With Active Autoimmune DiseasesWithdrawnNCT06548620Early Phase 1
• Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAVWithdrawnNCT06508346
• IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory MyopathyTerminatedNCT06462144Early Phase 1
• Iptacopan in Patients With ANCA Associated VasculitisActive, not recruitingNCT06388941Phase 2
• Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)Active, not recruitingNCT06294236Phase 1
• CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101Active, not recruitingNCT06152172Phase 1
• A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy ParticipantsCompletedNCT06004960Phase 1
• A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant MedicationsCompletedNCT06004947Phase 1
• A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168CompletedNCT05988021Phase 1
• A Study of CCX168 in Japanese and Caucasian Healthy Adult MalesCompletedNCT05988008Phase 1
• Avacostar - (PASS)Active, not recruitingNCT05897684
• An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesActive, not recruitingNCT05732402Phase 1/2
• Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the OriginatorCompletedNCT05716334

← Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis overview